Progranulin and GPNMB: interactions in endo-lysosome function and inflammation in neurodegenerative disease

J Neuroinflammation. 2023 Nov 30;20(1):286. doi: 10.1186/s12974-023-02965-w.

Abstract

Background: Alterations in progranulin (PGRN) expression are associated with multiple neurodegenerative diseases (NDs), including frontotemporal dementia (FTD), Alzheimer's disease (AD), Parkinson's disease (PD), and lysosomal storage disorders (LSDs). Recently, the loss of PGRN was shown to result in endo-lysosomal system dysfunction and an age-dependent increase in the expression of another protein associated with NDs, glycoprotein non-metastatic B (GPNMB).

Main body: It is unclear what role GPNMB plays in the context of PGRN insufficiency and how they interact and contribute to the development or progression of NDs. This review focuses on the interplay between these two critical proteins within the context of endo-lysosomal health, immune function, and inflammation in their contribution to NDs.

Short conclusion: PGRN and GPNMB are interrelated proteins that regulate disease-relevant processes and may have value as therapeutic targets to delay disease progression or extend therapeutic windows.

Keywords: Endo-lysosomal system; GPNMB; Immune system; Neurodegenerative diseases; Progranulin.

Publication types

  • Review

MeSH terms

  • Frontotemporal Dementia*
  • Glycoproteins / metabolism
  • Humans
  • Inflammation / metabolism
  • Lysosomes / metabolism
  • Membrane Glycoproteins / metabolism
  • Neurodegenerative Diseases* / metabolism
  • Progranulins / metabolism

Substances

  • Progranulins
  • Glycoproteins
  • GPNMB protein, human
  • Membrane Glycoproteins